Get started
Author

Serena Ruggieri

Observed names: Ruggieri, Ruggieri S, Ruggieri Serena, Ruggieri, S, Ruggieri, S., Ruggieri, Serena, S Ruggieri, S. Ruggieri, serena ruggieri
Observed institutions: University of Foggia, University of Rome Tor Vergata, University of Verona, Universitat Autònoma de Barcelona, Vita-Salute San Raffaele University, University of Campania "Luigi Vanvitelli", Dongguk University, University Hospital of Basel, Agostino Gemelli University Polyclinic, Istituto Neurologico Mediterraneo, Azienda Ospedaliera San Camillo-Forlanini, Ospedale San Filippo Neri, Vall d'Hebron Institut de Recerca, Amsterdam Neuroscience, Don Carlo Gnocchi Foundation, Azienda Ospedaliera Sant'Andrea, Vall d'Hebron Hospital Universitari, IRCCS San Camillo Hospital, IRCCS Ospedale San Raffaele, Fondazione Santa Lucia, National Hospital for Neurology and Neurosurgery, Carlo Forlanini Hospital, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, UCL Queen Square Institute of Neurology, University College London, Sapienza University of Rome, Icahn School of Medicine at Mount Sinai
ORCID: 0000-0001-5287-3290
Observed ORCID: 0000-0001-5287-3290
OpenAlex ID: A5045865733
Deep gray matter volume loss drives disability worsening in multiple sclerosis
2018 · Arman Eshaghi, Ferran Prados, et al. · Annals of Neurology · 451
PDF
Progression of regional grey matter atrophy in multiple sclerosis
2018 · Arman Eshaghi, Razvan V. Marinescu, et al. · Brain · 372
PDF
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis
2013 · Daniela F. Angelini, Barbara Serafini, et al. · PLoS Pathogens · 175
PDF
Longitudinal Assessment of Multiple Sclerosis with the Brain‐Age Paradigm
2020 · James H. Cole, Joel Raffel, et al. · Annals of Neurology · 154
PDF
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
2021 · Carla Tortorella, Alessandra Aiello, et al. · Neurology · 150
Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study
2017 · Massimo Filippi, Paolo Preziosa, et al. · The Lancet Neurology · 126
Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction
2019 · Gijs Kooij, Claudio Derada Troletti, et al. · Haematologica · 121
PDF
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration
2013 · H Kearney, MA Rocca, et al. · Multiple Sclerosis Journal · 113
PDF
Advances in spinal cord imaging in multiple sclerosis
2019 · Marcello Moccia, Serena Ruggieri, et al. · Therapeutic Advances in Neurological Disorders · 103
PDF
Shift of multiple sclerosis onset towards older age
2022 · Luca Prosperini, Matteo Lucchini, et al. · Journal of Neurology Neurosurgery & Psychiatry · 88
PDF
Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria
2023 · Angela Vidal-Jordana, Alex Rovira, et al. · Neurology · 86
PDF
Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome
2021 · Massimo Filippi, Paolo Preziosa, et al. · Neurology · 86
Nanovesicles from adipose-derived mesenchymal stem cells inhibit T lymphocyte trafficking and ameliorate chronic experimental autoimmune encephalomyelitis
2018 · Alessia Farinazzo, Stefano Angiari, et al. · Scientific Reports · 85
PDF
T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis
2015 · Gabriella Ruocco, Silvia Rossi, et al. · Clinical Science · 75
PDF
FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis
2018 · Manolo Sambucci, Francesca Gargano, et al. · Scientific Reports · 72
PDF
Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis
2017 · Susanna Amadio, Chiara Parisi, et al. · Frontiers in Immunology · 72
PDF
Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study
2020 · Luca Prosperini, Chiara Rosa Mancinelli, et al. · Neurotherapeutics · 69
PDF
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
2021 · Luca Prosperini, Serena Ruggieri, et al. · Neurology Neuroimmunology & Neuroinflammation · 64
PDF
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis
2016 · Luca Prosperini, Francesco Saccà, et al. · Journal of Neurology · 56
PDF
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
2018 · Luca Prosperini, Pietro Annovazzi, et al. · Journal of Neurology · 55
Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation
2018 · Marcella Reale, Erica Costantini, et al. · Scientific Reports · 55
PDF
Consensus Paper: Ataxic Gait
2022 · Pierre Cabaraux, Sunil K. Agrawal, et al. · The Cerebellum · 52
Lifespan normative data on rates of brain volume changes
2019 · Marco Battaglini, Giordano Gentile, et al. · Neurobiology of Aging · 52
Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis
2016 · Giacomo Lazzarino, Giacomo Lazzarino, et al. · Molecular Neurobiology · 52
Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis
2020 · Luca Prosperini, Chiara Mancinelli, et al. · Journal of Neurology Neurosurgery & Psychiatry · 51
Works count: 165
Citation count: 4,550
H-index: 37
I10-index: 87
Year
Topic
Type